

Subject Index

Actinomycin

- Paediatric sarcoma treatment 1125
- Trophoblastic disease combination therapy 696

Acute lymphoblastic leukaemia

- Bone marrow transplantation 156
- Chemotherapy, splenic abscess occurrence 1111
- Differential therapy 829

Acute megakaryoblastic leukaemia differentiation IFNs on 825

Acute myeloid leukaemia

- AML8 protocol and trials 826
- Combination therapy, splenectomy, long-term results 822
- FLAG chemotherapy 820
- MDR1 gene expression 605
- Mitoxantrone 821

Acute non-lymphocytic leukaemia bone marrow transplantation 152

Acute pro-myelocytic leukaemia

- All-*trans* retinoic acid therapy 203, 828
- Molecular and biological characterisation 185

Adjuvant chemotherapy

- Bladder cancer 49
- Breast cancer 34, 197, 278, 369, 374, 379, 390, 393, 395
- Colorectal cancer 491
- Compared, neoadjuvant endocrine 379, 384
- Gastric cancer 547
- Long-term morbidity after 10
- Neutropenia prevention 272
- Rectal cancer 22
- Renal cell tumours 19
- Small cell lung cancer 856
- Soft tissue sarcomas 11

α 1-Adrenergic receptors lung cancer 884

Adriamycin

- Bladder cancer 1297
- Breast cancer 380, 420
- Gastric cancer 549
- Non-Hodgkin lymphoma 973, 983
- On MDR cells 620
- Osteosarcoma 1035
- Renal cancer 1318
- Small cell lung cancer 857
- Soft tissue sarcoma 1018, 1025, 1039, 1050

AIDS

- B-cell lymphoma 215
- Kaposi's sarcoma 216, 220, 221
- Malignant lymphoproliferative diseases 214
- Non-Hodgkin lymphoma 213, 217, 218, 219, 975
- Palliative care problems in general hospital 1519
- Various malignancies 217

Aminogluthetimide breast cancer therapy 404, 450, 454

Amiodarone drug resistance modulation 611

- Ammonium-trichloro(dioxyethylene-0-0') tellurate (AS101) immunostimulatory action 158, 256
- Anal cancer 5FU, cisplatin therapy 558
- Anaemias erythropoietin on 259, 260, 268, 1173
- Anthracyclines
 Alopecia prevention 1437, 1514
 Late cardiac effects 1108
 Multidrug resistance 64, 65
 Peripheral T-cell lymphoma 979
 Resistance, breast cancer 413, 416, 424, 441, 449
- Anti-CEA antigen lung cancer staging 876
- Anti-emetic therapy
 Corticosteroid 1175
 DAU 6215CL 1158
 Dexamethasone 1149, 1159, 1161, 1164
 Diphenhydramine 1159
 Dutch survey 1483
 EORTC experience 1151
 Granisetron 1117, 1149, 1161, 1164, 1165, 1181
 5-HT₃ receptor antagonists 1150, 1158, 1166, 1485, 1491
 LAS 30451 1166
 Metoclopramide 1159
 Nursing care 1430
 Ondansetron 1150, 1151, 1159, 1175, 1178
 Quality improvement 1168
 Tropisetron 874, 999, 1119, 1150, 1155, 1178, 1179
- Antiprogestins breast cancer treatment 93
- AraC
 AML 820
 CML 836, 837
 Colorectal cancer 509
 Home treatment, elderly leukaemic patients 1467
- Aredia breast cancer treatment 398
- Aromatase inhibitors, breast cancer 94, 397, 404, 428, 450, 454, 461
- Arotenoid RO 40-8757 phase I trials 202
- ATP reversal of p-glycoprotein action 606
- AZT Hodgkin's disease 934
- Base excision repair of DNA 144
- Basic fibroblast growth factor (bFGF) receptors in breast cancer 92
- BCNU
 Breast cancer 431, 434
 Combination therapy 280
 Gliomas 1056
 Melanoma 1013
- Benzo(a)pyrene carcinogenesis 462
- Bladder cancer
 Categorisation and treatment 1279
 Chemoradiotherapy 1293, 1298, 1300, 1303
 Chemotherapy 1299, 1301

- Continent ileal reservoir 1289
- Cs-137 implantation 1294
- DNA ploidy 1290
- Epirubicin 1281
- IL-2 1304
- Neoadjuvant chemotherapy 1283, 1284, 1291, 1297
- Organ preservation 49
- Progression 1296
- Radiotherapy 1280
- Salvage cystectomy 1287
- Surgery 83
- Surgery and IFN 1288
- Thiotepa and BCG 1282
- Tumour markers 80, 1397

Bleomycin

- Head and neck cancer 779, 808
- Hodgkin's disease 931, 934
- Melanoma 1009
- Testicular cancer 1348, 1350
- Uterine cancer 708

BMJ-25067 phase I study 646, 652

Bone

- Fracture repair modulation 1160
- Marrow, breast cancer tumour cells 296, 383
- Metastases, pamidronate treatment 282
- Metastases, surgery 210, 1145
- Mineral density tamoxifen treatment 388, 399
- Paediatric salvage surgery 1122

Bone marrow transplantation

- ALL 156
- AML 152, 826
- AML8 protocol 826
- Antiemetic control of pretreatment 1155
- Breast cancer 266, 293
- Breast cancer chemotherapy 431, 433, 434
- CML 823, 824
- Combination chemotherapy 276, 280
- Conditioning poor-risk patients 840
- Different modes assessed 155
- Haemopoietic recovery after 151
- Hodgkin's disease 933, 961
- Neuroblastoma 153
- Non-Hodgkin lymphoma 961
- Solid tumours 154
- Tumour cell removal 848

Brachial plexopathy in breast cancer 297

Brachytherapy

- Brain tumours 1081
- Breast cancer 357, 361
- Cervical cancer 1255
- Colorectal cancer 502
- Dose rate effects 164
- Glioma 1060
- Gynaecological 165, 692, 697, 702, 706, 1276
- Head and neck cancer 168, 775, 816, 1277
- Irradiation helmet technique 1243
- Non-small cell lung cancer 886
- Oesophageal cancer 537
- Oral cavity 753, 754, 783, 785
- Quality assurance 1454

Soft tissue sarcoma 1029, 1030

Brain tumours

Biochemical findings 1075
 Brachytherapy 1081
 Cellular immunity 1070
 Childhood, radiotherapy 110
 Dexamethasone toxicity 1131
 DNA ploidy, proliferation potential 1219
 Glioblastoma diagnostic imaging 1051
 Metastases, surgery 211
 Neurological impairment 1072
 Oligodendrogliomas metastases, radiotherapy 1264
 Oligodendrogliomas PET studies 117
 p53 expression, status correlation 1097
 Phagocytic activity, levamisole 1066
 Sequelae of childhood treatment 1068
 Vascular malformations, radiotherapy 1062
 Vascularisation and necrosis 1074

Breast cancer

Adjuvant chemotherapy EC screening program 395
 Adjuvant chemotherapy Israel 390
 Adjuvant chemotherapy trial 369, 374, 379
 Adjuvant systemic therapy 34
 Adjuvant therapy benefit analysis 197
 Aminoglutethimide, trilostane comparison 454
 Anthracycline resistant 406, 407, 429
 Anthracyclines 420, 421, 422
 Antiprogesterin treatment 93
 Aromatase inhibitors treatment 94, 461
 Aredia assessment 398
 Associated brachial plexopathy 297
 Autologous bone marrow transplant, HDCT 393, 431, 433, 434
 Autologous progenitor cell support 365
 Axillary treatment prognosis 345
 BCNU high dose 431, 434
 BFGF in 92
 Bromocriptin, laureotide therapy 443
 C-erb B2 gene amplification prognosis 291, 427
 Carboplatin, vinorelbine 460
 Cathepsin D marker 136
 CEA levels, oestrogen receptor status 307
 Cells, decapeptyl action 665
 Cells, retinoids and tamoxifen inhibition 666
 Central small size, surgery 334
 Chemotherapy, clinical and histological responses 408
 Chemotherapy, haematologic toxicity prevention 261
 Chemotherapy short vs. long 458
 Cisplatin, epirubicin, vinorelbine study 439
 CMF chemotherapy time trial 400
 Combination chemotherapy 278, 631
 Conservation, prognostic factors 336, 344, 368
 Conservation therapy, Israel 342
 Conservative chemotherapy 354
 Conservative radiotherapy 351, 352, 359, 360, 1262
 Conservative surgery 15, 193, 196, 332, 335, 343, 347, 351, 355, 360, 361
 CPT II pharmacokinetics 601
 Cyclophosphamide high dose 417
 Cyclophosphamide, thiotepa 419
 Cytogenetics 131
 Cytological-histological grading 289
 D-Trp-6 therapy 452
 Diagnosis patterns 303
 DNA ploidy and S-phase prognosis 289, 290, 313, 314
 DRB-homozygous genotypes, prognosis 1091

- Ductal carcinoma *in situ* 344, 349, 355
Early detection Israel 311, 312
Echocardiography 298
Elderly women 350, 353, 378, 409
Epirubicin–cyclophosphamide trial 453
Epirubicin high-dose 426
Erlangen tumour marker 438
Familial patterns 39
FEC chemotherapy 444
FEC chemotherapy, folinic acid, thymostimulin 401, 436
FEC chemotherapy response time 405
FEC with granulocyte-CSF 432, 436
Fine needle aspiration biopsy 304
Follow-up after surgery 321
FTC, FAC chemotherapy comparison 402
5FU with leucovorin 416, 457
Gestragen with chemotherapy 447
Growth factors 252, 257
HER-2 gene 1089, 1096
Histological parameters, prognosis 325
Hormonal control 90
Hormonal receptor prognosis 135, 301, 317, 328
5-Hydroxyandrestone treatment 397, 428
IFN, tamoxifen 295, 456
IFN β on oncogene expression 1098
Immune defect 322
Immunodiagnosis 300
Immuno-endocrine homeostasis 305
Influence of age on treatment choice 373
Involved nodes, prognosis 288
“Informed consent” survey 1429
Infraclinical tumours screening 343
Liver metastases radiochemotherapy 440
Local recurrences 337, 341, 344, 347, 349, 357, 358
Locally advanced, treatments compared 412
Lonidamine combination therapy 377
Lonidamine, IFN, epirubicin 459
Losoxantrone chemotherapy 403
Luminal epithelial antigen prognosis 1099
Lytic effector cell function 323
3M treatment regimen 384, 415, 441, 488
Magnetic resonance imaging diagnosis 331
Maintenance therapy trial 372
Male, prognosis 286, 308
Markers immunocytochemistry 392
Mass screening 4, 103, 104, 107
Megestrol acetate with IFN 410
Metastasis model 299
Mucin-like proteins 138
Mucinous, pure and mixed comparison 314
Nodal irradiation 348
Non-palpable, needle biopsies 287, 320, 356
Non-palpable, surgery 333
Occult primary 340
Oestrogen receptor determinations 309
Oncogene, prognosis 427
Oncoprotein and laminin receptor markers 139
Oophorectomy 366
Ovarian obliteration or Zoladex 396
p53 expression 1088
Paget’s disease 349
PAI-1, prognosis 292
Patient experiences 1469
Phyllodes tumour, surgery 339
Plasma PDGF, prognosis 294, 330
Plasminogen activators, prognosis 316, 317, 327

- Preoperative chemotherapy 380, 382, 384, 391
- Preoperative flow cytometry 318, 391
- Primary chemotherapy 338
- Primary chemotherapy, conservation 50, 376
- Primary chemotherapy, prognosis 368, 386
- Prognosis, S-osteocalcin 310
- 17q association 1083
- Quadrantectomy and radiotherapy 364
- Quality assurance 194, 195
- Radiotherapy, dose rate effect 167
- Recurrence predictors 387
- Recurrent, hyperthermia RT or CT 337, 341
- Reproductive index prognosis 306
- Risk, tamoxifen prevention trial 371
- Salvage chemotherapy 411, 414, 422, 425, 449
- Second cancer risk after treatment 370
- Second-line hormone therapy 450
- Serine proteases 137
- Site-specific metastases prognosis 293
- Soluble tumour markers, predictors 315
- Somatostatin analogs treatment 91
- Surgery, menstrual cycle, prognosis 302
- Tamoxifen, aminogluthetimide 404
- Tamoxifen, long term treatment 388
- Tamoxifen, serum lipid levels 385
- Tamoxifen, thromboembolic risks 367
- Taxol, doxorubicin, G-SCF 636
- Taxol, G-CSF 435
- Taxol treatment 413, 423
- Taxotere 437
- Tegafur with folinic acid 451
- TFX-thymostimulin with radiotherapy 381
- TIL autologous tumour cell specificity 389
- TPS antigen, prognosis 319, 326, 327
- Treatment, quality of life 58, 448
- Tumour cells in bone marrow 296, 383
- Tumour markers 1367, 1368, 1369, 1377, 1381, 1382, 1383, 1389, 1390, 1391, 1396, 1400, 1405, 1407
- Vinorelbine (Navelbine) 418, 430, 446
- Vinorelbine, carboplatin 460
- Vinorelbine, mitomycin 407
- Vinorelbine mitoxantrone 406, 449
- Vinorelbine trial 445
- Vorozole pharmacology 394
- Vorozole trial 455
- Vorozole-racemate treatment study 442

- Bromocriptin breast cancer therapy 443

- Bromodeoxyuridine studies of cell proliferation 189

- Bronchial carcinoma, viral DNA evidence 467, 468

- Bryostatins I signal transduction inhibition, anti-cancer agent 157

- Burkitt's lymphoma, EBV virus effects 1110

- Busulfan-melphalan, bone marrow transplants 840

- Buthionine sulfoximine (BSO)-melphalan combination trial 647

- CA 125
 - Cisplatin conjugate 660
 - Evaluation of ELSA II assay 1373
 - In breast cancer 1396
 - In LAM 1372

- In ovarian cancer 17, 715, 720, 723, 745, 1384
- Cachexia, medroxy progesterone acetate treatment 1176
- Calcitonin nasal spray, pain management 1132
- Camptothecin analog CPT 11 pharmacokinetics and toxicity 601, 643
- Cancer treatment, local control 147, 148, 149, 150
- Carbogen
 - Administration on tumour oxygenation 1209
 - Glioblastoma radiotherapy 1254
- Carboplatin
 - Bladder cancer 1298, 1299, 1302
 - Breast cancer, combination 266, 278, 433, 460
 - Cervical cancer, combination 710, 739
 - Dose calculation, Calvert's formula 595, 1443
 - Oesophageal cancer 545, 559
 - Germ cell tumours, combination 276
 - Gliomas 1056
 - Head and neck cancer 759, 762, 766, 772, 780, 793, 795, 812
 - Hypersensitivity 1163
 - Liver cancer 561
 - Melanoma 1002, 1005, 1007
 - Non-small cell lung cancer 909, 923, 925
 - Ovarian cancer, combination 253, 280, 730, 743, 746, 751
 - Pharmacokinetics and toxicity 593
 - Radiation cross resistance 607
 - Small cell lung cancer 844, 852, 855, 860, 861, 862, 863, 865, 875
 - Testicular cancer 1348, 1350, 1351
 - Urothelial cancer 1295
 - Uterine cancer, combination 708
- Carcinogenesis
 - Cancer risk prediction 462
 - Gastric, role of salt 464
 - Genomic imprinting 466
 - Monoamine effects 465
 - Mutagenesis and chemical structure 463
 - Tumour-associated viral DNA 467, 468
- Cardiac disease, breast cancer therapies 298
- Carmustine breast cancer combination therapy 365
- Cathepsin D
 - Breast cancer marker 136, 137, 392
 - Ovarian cancer marker 728
- Catheters
 - Argentinian survey 1156
 - Comparison of problems 1455
 - Intraperitoneal 628
 - Long-term central venous access 1452
 - Paediatric patients 1446
 - Problems with implantable 1292
 - Solid tumours, Hickman line 1170
 - Survey for ambulatory infusional therapy 1488
- CCNU
 - Anaplastic astrocytoma 1079
 - Melanoma 1009
 - Renal cancer 1313
- CD44 (transmembrane glycoprotein) variants in metastases 23, 84

CEA levels in breast cancer 307

Cell

- Differentiation p53 induced 30, 96
- Proliferation as tumour predictor 189, 191
- Receptors 84, 85, 86, 87, 88, 89
- Response to radiation 14

Cervical cancer (see also Gynaecological cancer)

- Brachytherapy 1255
- Combination infusion chemotherapy 631
- Hypoxia measurement 188
- Laparoscopy 77
- Oncogene rearrangement, radiosensitivity 1228
- Patient care continuity 1447
- Prognosis, p53 and EFGr expression 1094
- Prognosis, treatment of early 28
- Radiotherapy dose-rate effects 163, 208
- Radiotherapy morbidity 54
- Radiotherapy, MRI monitoring 1266, 1267
- Radiotherapy, non-homogeneous 122
- Screening in Europe 105
- Tumour marker 1394, 1404
- Vascularisation 187

Chemoembolisation

- Liver cancer 544, 561, 562, 567
- Rat tumour system 657

Chemotherapy

- Antisense oligonucleotides 160
- Biological response modifiers 161
- Chemofiltration 625
- Circadian modulated continuous infusion 630
- CNS tumours 1051, 1059, 1064, 1067, 1071, 1073
- Combination, carcinoma of unknown origin 572
- Continuous infusion, outpatient 1413, 1414, 1418
- Drug disposition and activity 624
- Drug resistance analysis 190, 191
- For larynx preservation 52
- For resectable breast cancer 50
- Hickman line catheter, solid tumours 1170
- High-dose, plasma antioxidant status 634
- 24-h combination infusion 631
- Hyperthermic limb perfusion 626
- Implantable port-catheter 1156
- In the elderly 13
- Induced anaemia prevention 259, 260, 261, 263, 270, 271, 272, 273, 275
- Induced growth hormone deficit 1107
- Infusion bag preparation 629
- Infusion 5FU, folinic acid, IFN 654
- Intra-aortic infusion 627
- Intraperitoneal catheters 628
- Isolation perfusion, melanoma 635
- Maximal tolerated dose 158
- Mesothelioma 1046
- Mitoxantrone combination, breast cancer 362
- N or EVCF regimen in breast conservation 354
- Oral assessment instrument 1435
- Out-patient, hospital environment 1439
- Patient preparation meeting 1456
- Paediatric parenteral nutrition 1110
- Polymer-drug conjugates 162
- Preoperative in children 33
- ProMACE-MOPP program 967
- Quality assurance 1459, 1460

- Reduction of side-effects 1484, 1485
- Retinoids 202, 203, 204
- Rhabdomyosarcomas in children 26
- Signal transduction inhibitors 157
- Split-dose vinblastine 633
- Wilm's tumour 111
- Childhood tumours (see Paediatric cancer)
- 2-Chlorodeoxyadenosine, hairy cell leukaemia 842
- Chlorpromazine, dexamethasone paediatric anti-emetic 1117
- CHOP chemotherapy non-Hodgkin lymphoma
 - Italian evaluation 987
 - U.K. review 973
- Chromosome structure atomic force microscopy studies 1092
- Chronic lymphatic leukaemia
 - Albumin prognosis 833
 - Familial study 179
 - Fludarabine 819, 841
- Chronic myeloid leukaemia
 - Allogenic bone marrow transplant 823, 824
 - IFN, cytogenic response 837
 - IFN treatment regimes 831
 - IFNs on progenitor cell binding 264
 - Myofibrosis 832
 - Polymerase chain reaction prognosis 835
 - Responses to high-dose chemotherapy 836, 837
- Cirrhosis
 - Lidocaine test 564
 - Liver cancer, transplant 543
- Cisplatin
 - Anal cancer 558
 - Bladder cancer 1297, 1298, 1300, 1302
 - Breast cancer combination therapy 338, 365
 - CA-125 conjugate 660
 - Chemoembolisation microcapsules 657
 - Colorectal cancer combination therapy 495
 - DNA adducts determination, specific antibodies 192
 - Emesis control 1150, 1151, 1158, 1159, 1161, 1166
 - Gastric cancer therapy 549, 560, 566, 573, 579, 581
 - Germ cell tumour 1059
 - Head and neck cancer 756, 765, 767, 768, 771, 774, 777, 779, 784, 787, 791, 794, 796, 797, 800, 801, 804, 808, 812, 813, 814, 817
 - Intrapericardial 591
 - Liver cancer 590
 - Melanoma 279, 996, 997, 1005, 1009, 1013
 - Mesothelioma 885, 1027
 - Neuropathy prevention 1152
 - Non-Hodgkin lymphoma 964, 983
 - Non-small cell lung cancer 877, 878, 879, 880, 881, 888, 891, 894, 896, 898, 900, 905, 906, 913, 917, 919, 920, 926, 927, 928
 - Oesophageal cancer therapy 557, 559, 1233
 - Osteosarcoma 1035
 - Ovarian cancer 720, 721
 - Ovarian cancer after surgery 736
 - Ovarian cancer combination therapy 725, 726, 739, 740, 751
 - Pancreatic cancer 553
 - Small cell lung cancer 845, 869, 873
 - Soft tissue sarcoma 1045
 - Testicular cancer 1347, 1348, 1351, 1352

- Therapy 277, 279, 425, 439, 509
- Toxicity procainamide effects 670
- Urothelial cancer 1295
- Uterine cancer combination therapy 708
- Cisplatin-procaine complex DPR, cytotoxic activity 671
- Clinical trials
 - Altered fractionation radiotherapy 206, 208
 - CHART 207
 - Etrinate-IFN combination 226
 - IL-2 224
 - IL-2-IFN 243
 - IL-2-melatonin 232
 - Immunotherapy, metastatic renal carcinoma 225, 233
 - PET studies 114
 - Retinoids 201, 202, 204
- Clodronate, metastatic bone pain 1130
- Cockayne syndrome, inherited NER defects 141, 146
- Colony-stimulating factors
 - Combination therapy AML 821
 - Combination therapy breast cancer 266, 278, 284
 - Combination therapy head and neck cancer 803
 - Combination therapy non-small cell lung cancer 927
 - Combination therapy ovarian cancer 265, 743, 746
 - Combination therapy small cell lung cancer 863
 - In breast cancer 252
 - Reduction of haemolytic toxicity by 259, 261, 263, 269, 270, 271, 272, 273, 274, 275, 277
- Colorectal cancer
 - Adjuvant therapy 25
 - Adjuvant therapy macrophage activation 491
 - AraC, cisplatin salvage evaluation 509
 - Blood transfusions prognosis 473
 - Chronotherapy-surgery program 524
 - Conservative management 522
 - Cytogenetics 132
 - Development 186
 - Elective surgery, risk factors 505
 - Familial predisposition 40
 - Flow cytometry and immunochemistry prognosis 479, 529
 - 5FU, folinic acid, fotemustine 523
 - 5FU, folinic acid, IFN 487, 521, 528
 - 5FU, folinic acid, thymostimulin 470
 - 5FU, folinic acid, vinorelbine 532
 - 5FU, 6S-folinic acid 587
 - 5FU, ftorafour, mitomycin 489
 - 5FU, IFN, leucovorin 494
 - 5FU, IFN, PALA 493
 - 5FU, IFN regimens 483
 - 5FU, leucovorin 496, 520
 - 5FU, levofolinic acid, HU 500
 - 5FU, MTX, leucovorin 471
 - 5FU, MTX, levofolinic acid 525
 - 5FU, phagocytic functions 482
 - 5FU tumour response monitoring 492
 - Hepatic metastases prognosis 469
 - Human papilloma virus 475
 - IFN vs placebo study 513
 - Immune dysregulation 518, 519
 - Intra-arterial combination chemotherapy 495, 503, 527
 - Intraperitoneal chemotherapy with haemofiltration 527
 - Laparoscopic guided brachytherapy 502

- Laparoscopic surgery considerations 73
 - Late result of surgery 481
 - Liver metastases, resection 209
 - Lung metastases, IFN 520
 - Mitomycin evaluation 510
 - Monoclonal antibody treatment 238, 267
 - Multimodality staging 516
 - Neovascularisation 486
 - Oxaliplatin trial 511
 - p563 and Ki-Ras alterations 530
 - Perioperative immunological state 533
 - Perioperative radiochemotherapy 534
 - Postoperative infusion procedures 484
 - Postoperative radiotherapy 476
 - Preoperative radiotherapy 474, 1265
 - Radical radiotherapy 515
 - Radical rectal resection 526
 - Radioimmunoscinigraphy 478, 480
 - Radiotherapy and Razoxane 508
 - Radiotherapy and tegafur 498
 - Radiotherapy vs. radiochemotherapy trial 536
 - Recurrences MRI, ECT follow-up 517
 - Recurrent disease, CEA prognosis 501
 - Sandwich radiotherapy 479
 - Scintigraphy 111-In-Cyt-103 512
 - Screening in Israel 102
 - Screening program Hemocult Sensa 507
 - Screening, various trials 106, 107
 - Smoking as a risk factor 504
 - Soluble lymphocyte activation molecules 518, 519
 - Structuredness cytoplasmic matrix test 477
 - Surgery, anastomosis choice 506
 - Surgery in elderly 472
 - Surgical and adjuvant treatment 22
 - Taxotere therapy 535
 - Thymidylate synthase prognosis 485
 - Topotecan therapy trial 490
 - Tumour markers 1370, 1398, 1406
 - Venous invasion prognosis 531
 - Young patients 514
- Conformal therapy
- Assessment 120
 - Heavy charged particles 123
 - Pelvic radiotherapy 121
 - Prostate cancer 1333, 1334
- Corticosteroid antiemetic in chemotherapy 1175
- Cyclophosphamide
- Breast cancer 266, 278, 284, 365, 374, 376, 380, 390, 400, 401, 405, 422, 433, 436, 444, 453
 - Breast cancer high-dose 417, 419
 - Hodgkin's disease 931
 - Non-Hodgkin lymphoma 973, 983
 - Ovarian cancer 253, 739, 740, 742, 746, 751
 - Small cell lung cancer 283, 869
 - Soft tissue sarcoma 1025
- Cyclosporine A multidrug-resistant cells 622
- CYFRA 21-1 tumour marker 1365, 1393
- Cytogenetics
- Breast tumour 131
 - Colorectal tumours 132
 - Mesenchymal tumours 133

- Renal tumours 134
- Testicular germ cell tumours 130
- Cytokines
 - Development for clinical application 48
 - Gene transduced tumour cells 46
 - Regional infusions and perfusions 45
 - mRNA levels in tissues 222
 - Stimulated haematopoiesis 255
 - Therapy, mouse model 223
 - Therapy with monoclonal antibodies 267
- D-Trp-6 breast cancer therapy 452
- Dacarbazine (DTIC)
 - Melanoma 999, 1002, 1004, 1005, 1011, 1012, 1013, 1199
 - Soft tissue sarcoma 1025
- DAU 6215CL antiemetic treatment 1158
- Daunorubicin accumulation, prognosis 616, 621
- Decapeptyl (DEC)
 - Antiproliferative activity, oestrogen requirement 665
 - Ovarian cancer 731
- Dexamethasone
 - Antiemetic 1149, 1159, 1161, 1164
 - Non-Hodgkin lymphoma 964
 - On lung cancer cell lines 889
- Differentiating drugs
 - Haematopoietic cytokines 8
 - Retinoids as model 7
- Diphenhydramine antiemetic treatment 1159
- Distamycin derivative FCE 24517 phase 1 study 650
- DNA
 - Alterations in carcinogenesis 16
 - Amplification and antimetabolite resistance 61
 - Double strand breaks, radiosensitivity 1226
 - Ploidy, bladder cancer 1290
 - Ploidy, brain tumours 1219
 - Ploidy, breast cancer prognosis 289, 290, 313, 324
 - Ploidy, endometrial cancer prognosis 689
 - Ploidy, head and neck cancer prognosis 818
 - Ploidy, non-small cell lung cancer prognosis 921
 - Ploidy, soft tissue sarcoma prognosis 1016
 - Topoisomerase II inhibitors 62
- DNA repair
 - Base excision 144
 - Cisplatin adducts 192
 - Defects and cancer proneness 146
 - Drug resistance 190
 - Inherited defects in nucleotide excision system 141
 - Oxidative damage, HAP1 protein 142
 - PolyADP-ribosylation 143
 - Radiation damage 14, 1208
 - Role of topoisomerases 145
- Doxorubicin
 - Cardiotoxicity reduction 658
 - Combination therapy 283, 402, 582, 636

- Microspheres activity 624
- Ovarian cancer combination therapy 740
- With ICRF-187, ion level concentrations 1172
- Droloxifen pharmacokinetics 594
- Dysphagia palliation, comparison of treatments 1147
- Dyspnea, morphine treatment 1127
- E-cadherin suppression of tumour invasion 87
- Elderly patients
 - Breast cancer 350, 353, 378, 1466
 - Chemotherapy 13
 - Colorectal cancer 472
 - Leukaemia, home-care treatment 1467
 - Testicular cancer 1358
- EO9 phase 1 study 637
- Epidemiology
 - Antineoplastic drugs risks to medical personnel 678
 - Cancer incidence in Estonian migrants to Sweden 683
 - Cancer incidence in physicians, dentists and health-care workers 679
 - Costing hospital trials 674
 - Head and neck cancer registry Northern France 680
 - Head and neck squamous cell carcinoma France 681
 - Israeli study, Chernobyl health effects 673
 - Long-term relative survival rates 675
 - Lung cancer age and clinical characteristics 682
 - Polish myeloma multiplex 686
 - Spanish laryngeal carcinoma, influence of radiation 687
 - Swedish cancer, Chernobyl fallout 676
 - Turkish cancer patients, hepatitis C antibody 684
 - Turkish lung cancer 677
- Epidermal growth factor
 - On lung cancer cell lines 251
 - Receptor in breast cancer 257
 - Receptor in ovarian cancer 262
- Epidoxorubicin
 - Combination therapy 278
 - Non-small cell lung cancer 897
- Epirubicin
 - Breast cancer 284, 338, 376, 401, 405, 411, 414, 420, 426, 427, 436, 439, 444, 453, 458, 459
 - Gastric cancer 566
 - Head and neck cancer 800
 - Hodgkin's disease 931, 934
 - Non-small cell lung cancer 906, 919, 927, 928
 - On left ventricular ejection fraction 597
 - Renal cancer 1315
 - Small cell lung cancer 857, 862, 863
- Epstein-Barr virus (EBV)
 - Burkitt's lymphoma cell integration effects 1100
 - Gene product BHRF1 1090
- Erythropoietin treatment of chemotherapy-induced anaemia 259, 260, 268, 1173
- Etanidazole clinical trials 68, 69
- Etoposide (VP-16)

- Actinomycin, trophoblastic disease 696
 - Breast cancer combination therapy 411
 - CML 836
 - Comparison with water-soluble phosphate 584
 - Gastric cancer 566, 581
 - Hodgkin's disease 931
 - Mesothelioma 914, 1027
 - Non-Hodgkin lymphoma 964, 977
 - Non-small cell lung cancer 878, 880, 888, 894, 898, 905, 909, 919
 - Oesophageal cancer 557
 - Ovarian cancer combination therapy 743
 - Pharmacokinetics and toxicity 593, 599
 - Small cell lung cancer 844, 850, 852, 855, 857, 860, 861, 862, 863, 865, 873, 875
 - Testicular cancer 1347, 1348, 1350
 - Urothelium 1286
 - With radiation on mouse tumour and feet 1211
- Etretinate
- Head and neck cancer 805
 - IFN combination therapy 226
- Ewing tumours
- Bone marrow transplantation 154
 - Limb salvage 1040, 1043
 - Long-term analysis 1104, 1121
 - Optimal chemotherapy in children 1125
 - p53 mutations 37
 - Prospective study 1015
- Extracyt, prostate cancer 1325
- Extravasation of cytostatics, management 1153
- Familial patterns
- Breast cancer 39
 - Colorectal cancer 40
 - Lung cancer 42
 - Multiple endocrine neoplasia 38
 - p53 gene 37
 - Site correlations 41
 - Testicular cancer 1362
- Family cancer screening 107
- Fluorouracil, bladder cancer therapy 1300
- Fibroblasts differentiation after irradiation 1215
- Filgrastin (CSF) neutrophil recovery 271, 272, 273, 283
- Fludarabine
- AML therapy 820
 - CLL therapy 819, 841
 - Metabolism, G-CSF on 585
- Flunarizine modulation of drug activity 617
- F-18-Fluorodeoxyglucose PET studies in patients 119, 1019
- Fluorouracil (5FU)
- Anal cancer 558
 - Breast cancer 278, 338, 362, 374, 376, 390, 400, 401, 402, 405, 416, 429, 436, 444, 457
 - Cardiotoxicity 600
 - Cervical cancer 710
 - Clinical pharmacodynamics 586

- Colorectal cancer 470, 471, 482, 483, 487, 489, 493, 494, 495, 496, 520, 521, 523, 525, 528, 532, 587, 654
- Gastric cancer 540, 560, 566, 573, 581
- Head and neck cancer 757, 759, 760, 761, 762, 765, 766, 768, 774, 777, 784, 791, 793, 794, 796, 797, 804, 808
- Non-small cell lung cancer 900
- Oesophageal cancer 549, 559, 1233
- Ovarian cancer 738, 747
- Pancreatic cancer 553, 582
- Prostate cancer 1328, 1336
- Renal cancer 1311

- Flutamide prostate cancer treatment 1343

- Folinic acid
 - Breast cancer 401, 436, 451
 - Colorectal cancer 470, 487, 521, 523, 528, 532, 587, 654
 - Gastric cancer 540
 - Head and neck cancer 774
 - Pancreatic cancer 553

- Fotemustine
 - Colorectal cancer 523
 - Gliomas 1055
 - Melanoma 997, 1010
 - Non-small cell lung cancer 890, 891, 892
 - With radiotherapy on lung cancer cells 1216

- Ftorafour colorectal cancer therapy 489

- FUDR (fluorodeoxyuridine)
 - Continuous infusion 630
 - Reversal of MDR 614

- Gallbladder cancer
 - Follow-up, biological markers 569
 - Treatment assessment 577

- Gastric cancer
 - Adjuvant chemotherapy 272, 547
 - Ambulatory chemotherapy 1413
 - Cisplatin with Mg 579
 - Cure 554
 - Disseminated intravascular coagulation 1171
 - Etoposide, adriamycin, cisplatin 549
 - Forms of gastrinoma 546
 - 5FU, cisplatin 560
 - 5FU, etoposide, cisplatin 581
 - 5FU, etoposide, epirubicin, cisplatin 566
 - 5FU, folinic acid, IFN 540
 - 5FU, leucovorin, cisplatin 573
 - HER2/*neu* prognosis 1096
 - Local recurrence 574
 - Lymphoma surgery 555
 - Neoadjuvant therapy 576
 - Preoperative immunotherapy 578
 - Preoperative radiotherapy 1257
 - Radiotherapy regimen 556
 - Surgery midstomach 570
 - Surgery vs palliation 571
 - Taxotere trial 539
 - Tumour-penetrating lymphocytes 568

- Gemcitabine
 - non-small cell lung cancer 882, 893
 - Pancreatic cancer 541
 - Phase I studies 645

Gene

- Alterations and drug responses 190
 - Alterations in childhood neuroblastoma 1084
 - APC and colorectal cancer 40
 - bcl-2* in Chinese follicular lymphoma 972
 - Clonal rearrangement non-Hodgkin lymphoma 958
 - DRB locus allelic distribution, breast cancer 1091
 - H19, tumour suppressor function 1093
 - HER2/*neu* (=c-*erbB-2*) breast cancer prognosis 291, 427, 1089, 1096
 - Ig in CLL 179
 - Imprinting in tumorigenesis 444
 - Interphotoreceptor binding protein 177
 - Of autosomal recessive disorders 24
 - Of endocrinopathies 38
 - p53 30, 37
 - p53 and EGFR, cervical carcinoma 1094
 - p53 expression immunoassay 1097
 - p53 expression, ovarian cancer 1086
 - p53 immunohistochemistry and cytosol assay 1088
 - p53 mutant, germ cell cancers 1087
 - p53 mutations, prognosis 1085
 - 17q, familial breast cancer 39, 1083
 - 17q, possible ovarian cancer link 1083
 - Retinoblastoma in non-Hodgkin lymphoma 957
 - Transfection factors in tumours 182
 - Tumour rejection antigens 2
 - Tumour suppressor 1, 6, 9, 24, 1093
 - Wilm's tumour 175
- Gestagen (medroxy progesterone acetate, MPA) breast cancer treatment 447, 450
- Glioblastoma, radiotherapy with nicotinamide 1230
- Gosevelin prostate cancer treatment 1338
- Granisetron (Kytril) antiemetic
- In chemotherapy 1117, 1149, 1161, 1164, 1165
 - In radiotherapy 1250
- Granulocyte colony stimulating factor (G-CSF)
- Breast cancer chemotherapy 432, 435, 436, 488, 636
 - On fludarabine and ara-C metabolism 585
- Growth factors
- Anaemia prevention 259, 260, 261, 263
 - bFGF 31
 - Haemopoietic 27
 - In breast cancer 252, 257, 294, 330
 - In chemotherapy 8, 13
 - In haemetopoiesis 255
 - In lung cancer patients 256
 - In ovarian cancer 262
 - In thrombocytopenic patients 254
 - On lung cancer cell lines 251
 - Radiation-induced 250
- GST π gene expression in sarcomas 609
- Gynaecological cancer
- Cervix 5FU, carboplatin 710
 - Cervix HicA-radiotherapy 693
 - Cervix Israel experience 699
 - Cervix lymphocyte ratio, smoking habits 713
 - Endometrial cancer etiocholanolone cholesterol relation 698
 - Endometrial cancer, ploidy and S-phase prognosis 689, 690
 - Endometrial cancer surgery, radiotherapy 705, 716

Fallopian tube carcinoma clinical experience 709
Israel pap-smear results 711
Magnetic resonance imaging 712
Ovarian Au-198 treatment 748
Ovarian CA-125 prognosis 745
Ovarian carboplatin cyclophosphamide, G-CSF 746
Ovarian cathepsin D marker 728
Ovarian cisplatin therapy 720, 721
Ovarian cisplatin, treosulfane 725, 726
Ovarian combination chemotherapy outcome 732, 739, 740, 743, 744, 751
Ovarian cyclophosphamide, Pt 742
Ovarian decapeptyl 731
Ovarian distant metastases 750
Ovarian oestrogen production marker 734
Ovarian 5FU, mitomycin 738, 747
Ovarian hyperfractionated radiotherapy 749
Ovarian IFN after chemotherapy 737
Ovarian ileus surgery 724
Ovarian intervention debulking surgery 718
Ovarian mitoxantrone, ifosfamide therapy 735
Ovarian multimodal therapy 733
Ovarian preoperative diagnosis 715
Ovarian residual tumour 744
Ovarian Scottish treatments 717
Ovarian second effort surgery 719
Ovarian supradical surgery 727
Ovarian surgery, cisplatin 736
Ovarian taxol, CA-125 response 723
Ovarian topoisomerase II detection 741
Ovarian topotecan treatment 722
Ovarian treosulfan 729
Ovarian treosulfan, carboplatin 730
Preservation of ovary function 701
Radiotherapy 700
Radiotherapy complications 695
Radiotherapy, late effects 706
Radiotherapy, surgery 697, 703
Trophoblastic disease, actinomycin, etoposide 696
Uterine carcinoma combination chemotherapy 708
Uterine carcinoma radiotherapy 707, 1258
Uterine sarcoma clinical experiences 694
Vagina, cervix brachytherapy 692, 702
Vaginal reconstruction 704
Vulvar cancer aetiology 691
Vulvar chemoradiotherapy 714

Haematological disorders

Gastrointestinal selective decontamination 827
MDR P-glycoprotein in 613
MDR S9788, verapamil, cyclosporine A comparison 622

Haematopoiesis control in cell culture 8

Haemoblastosis immunodeficiency 839

Haemopoietic growth factors, clinical evaluation 27

HAP1 protein, DNA repair 142

Head and neck cancer

Adenoid cystic carcinomas, mitoxantrone 770
Chemoradiotherapy 756, 760, 765, 784, 787, 791, 794, 796, 797, 801, 803, 804, 812, 817, 1269
Chemotherapy-induced anaemia prevention 259
Combination chemotherapy 759, 761, 762, 772, 774, 777, 798, 808
Combination infusion chemotherapy 631

- Drugs cytotoxicities 767
- Etanidazole trials 68, 69
- Glutathione marker 1225
- Hyper and accelerated fractionation radiotherapy 206, 207, 208
- Hyperthyroidism after radiotherapy 1272
- Ir-192 implant 816
- IFN, radiotherapy combination 241
- Larynx preservation chemotherapy 52
- Metastases p53 gene mutations 1085
- Metastatic patterns 811
- Mobile tongue radiotherapy 753, 785
- Nasopharyngeal, biological characteristics 806
- Nasopharyngeal chemoradiotherapy 800, 813, 814
- Nasopharyngeal, northern Israel 788
- Nasopharyngeal retrospective analysis 752, 764, 814
- Neoadjuvant chemotherapy 588, 757, 779, 780, 793, 794
- Oncogene amplification 790
- Oral cavity preoperative chemotherapy assessment 799
- Oral cavity radiotherapy 754
- Oropharyngeal clinical prognosis 782
- Oropharyngeal transmandibular resection 786
- Paranasal sinuses 798
- Postablative reconstruction 792
- Postoperative radiotherapy 809
- Prognostic factors 815, 818
- Psychological coping study 1497
- Pulsed-dose-rate brachytherapy 168
- Radiotherapy 755, 763, 764, 769, 773, 775, 776, 783, 1239
- Radiotherapy nursing standard 1433
- Reconstructive surgery 36
- Salivary gland diagnosis 789
- Second primaries prevention 805
- SPEC-SCC immunoscintigraphy 755
- Taxotere study 758
- Thyroid 778, 781, 791
- Thyroid prognosis 807

HIV-related disease (see AIDS)

Hodgkin's disease

- Antiretroviral treatment 934
- β_2 microglobulin prognosis 937
- Blood products transfusion 953
- Bone marrow transplant 933, 961
- Bone metastases 941
- Cell lines growth in SCID mice 929
- Chemoradiotherapy 930, 939, 943
- Chemotherapy 931, 934, 938, 941, 944, 949, 950, 951
- In children 109, 941, 944, 945
- Infradiaphragmatic 950
- Karyotype analysis 956
- Peripheral blood progenitor cell transplant 959
- Prognostic factors 938, 939, 940, 948, 956
- Radiotherapy 109, 930, 933, 937, 938, 939, 947, 952, 954, 955
- Retrospective analysis 932, 939, 947
- Second malignancies 935, 936, 939, 942
- Staging for therapy 938, 943, 946
- Vinorelbine treatment 949

Home care

- Domiciliary assistance 1133
- Dutch technology 1510
- G.P. consultative service 1138
- Hospice service 1137
- Israel program 1509

Hormones, breast cancer 90, 135, 301, 305

- Hospice
 - Home care 1137
 - Israel experience 1134
 - North London multicultural 1517
- Human papilloma virus, anal carcinoma 475
- 4-Hydroxyandrestosterone, breast cancer treatment 397, 428
- Hydroxyurea (HU) combination therapy 500, 768
- Hyperthermia
 - Enhanced TNF α 659
 - Recurrent breast cancer 337, 341
 - With chemotherapy, liver cancer 644
 - With chemotherapy, renal cancer 1318
 - With chemotherapy, soft tissue sarcoma 651
 - With radiotherapy 1270, 1275, 1335
- Hypothermia prevention of anthracycline-induced alopecia 1437, 1514
- ICRF-187 with doxorubicin on ion concentrations 1172
- Idarubicin CML treatment 836
- Idiopathic pulmonary fibrosis CA19-9 level 1402
- Ifosfamide
 - Breast cancer 411, 414
 - Germ cell tumours 276, 277
 - Head and neck cancer 772, 780, 810
 - Non-Hodgkin lymphoma 964, 977, 981
 - Non-small cell lung cancer 880, 897, 906, 917
 - Ovarian cancer 735, 743
 - Paediatric solid tumours 1106
 - Pharmacokinetics, child's age 602
 - Pharmacokinetics, hyperthermia 663
 - Renal cancer 1314
 - Small cell lung cancer 857, 867
 - Soft tissue sarcoma 1018, 1050
 - Testicular cancer 1347
 - Toxicity 592
 - Uterine cancer 708
 - Urothelium 1286
- Imipenem low dose for neutropenia 1180
- Immunodeficiency in haemoblastoses 839
- Immunohistochemistry prognostic factors 140
- Immunotherapy
 - IFN-induced antiphospholipid antibodies 229
 - IL-2 activated lymphocytes 43, 233
 - IL-2 and IFN 225, 233
 - IL-2 in metastatic malignancies 224
 - Melanoma 1002
 - Monoclonal antibody 238
 - Pineal function 232
 - To offset immunosuppressive therapy 231
 - Tumour regulation antigens 2
- Indomethacin stimulated NK activity 231
- Integrins and metastases 85

Interferon α (IFN)

- Bladder cancer 1288
- Breast cancer 410, 456, 459
- CDDP combination 279
- CML treatment regimes 831
- Colorectal cancer 483, 493, 494, 513, 521, 528, 654
- Gastric cancer 541
- Glioblastoma 1063
- Hairy cell leukaemia 830
- Head and neck cancer 777
- IL-2 combination, renal cancer 243, 1308, 1309, 1316
- Liver metastases 235
- Melanoma 996, 1002, 1005, 1009, 1012, 1013
- Mesothelioma 885
- Mitomycin C combination 281
- Non-Hodgkin lymphoma 962, 965, 968, 982
- On megakaryocytic differentiation 825
- On progenitor cell binding 264
- Ovarian cancer 47, 737
- Radiotherapy combination 234, 241
- Renal cancer 47, 1311, 1314, 1315, 1318
- Retinoid combination 202, 227, 233
- Retinoid, radiotherapy 230
- Roferon treatment of melanoma 239
- Stimulated NK activity 231
- Tamoxifen combination therapy 295

Interferon β

- Colorectal cancer therapy 487, 533
- On growth factor production 250
- On megakaryocyte differentiation 825
- Recombinant breast cancer oncogenes 1098

Interferon γ

- On megakaryocyte differentiation 825
- On progenitor cell binding 264
- Periodic variation in melanoma 242
- Sarcoma therapy 1017

Interleukin 2 (IL-2)

- Activated lymphocytes and IFN 233
- Bladder cancer therapy 1304
- Colorectal cancer therapy 518, 519, 529
- IFN combination, renal cancer 243
- Immunotherapy, metastatic cancer 43
- LAK cell combination, renal cancer 444
- Melanoma therapy 996, 1002, 1011
- Melanoma vaccine on immune response 228
- Melatonin clinical trial 232
- Phase II trial, metastatic tumours 224, 225
- Radiotherapy on metastasis 246
- Receptor, periodic variation in melanoma 242
- Renal and ovarian cancer treatments 47
- Therapy and phagocytosis 247
- With antibiotic, prophylaxis 245

Interleukin-3 with ovarian cancer chemotherapy 265

Interleukin-6

- On megakaryocyte differentiation 825
- Renal cancer treatment 1312

JM 216 (Pt drug) phase I trial and pharmacokinetics 638

Kaposi's sarcoma

- Photodynamic therapy 1183
- Progression and HIV status 216
- Radiotherapy 220, 221, 1240
- Treatments 217
- Ki-Ras, colorectal cancer 530
- KW-2149 phase I and pharmacokinetic trial 641
- Laminin on cell differentiation 1077
- Laminin receptors
 - As tumour marker 139
 - In metastasis 85, 86
- Lanreotide breast cancer therapy 443
- Laparoscopic surgery
 - Colorectal cancer 73
 - Ovarian cancer 74
 - Pelvic and aortic dissection 77
 - Urological cancer 83
- LAS 30451 antiemetic treatment 1166
- Lenograstin (CSF)
 - Neutrophil recovery 285
 - Small cell lung cancer 846
 - Soft tissue sarcoma 1034
- Leucovorin
 - Bladder cancer 1301
 - Breast cancer 416, 429, 457
 - Colorectal cancer 471, 494, 495, 496, 520
 - Gastric cancer 573
 - Oesophageal cancer 545
 - Tegafur, phase I study 648
- Leukaemias
 - Bone marrow transplants, poor risk patients 840
 - Daunorubicin accumulation 616, 621
 - Hairy cell 2CdA therapy 842
 - Hairy cell, hepatic infiltration 830
 - Molecular genetics 101
 - p-Glycoprotein 608, 621
 - Transformation of CML 843
- Levamisole brain tumour phagocytic activity 1066
- Levofolinic acid, colorectal cancer 500, 525
- Liarozole fumarate antitumour action 672
- Liarozole hydrochloride (R 75251), prostate cancer 1326
- Lidocaine, liver cancer 564
- Li-Fraumeni syndrome 178
- Liposomal muramyl tripeptide phosphatidylethanolamine, soft tissue sarcoma treatment 1026
- Liver cancer
 - Combination chemotherapy 281
 - Chemoembolisation 544, 561, 562, 567
 - Cisplatin 590

- Hyperthermia and chemotherapy 644
- Lidocaine test 564
- Liver transplant 543
- Metastases, breast cancer 440
- Metastases, colorectal cancer 469, 1139
- Multistage evolution 181, 184
- Thymostimulin 236, 237
- Lonidamine
 - Breast cancer 377, 459
 - Mechanism of action 662
 - Modulation of drug activity 617
 - Non-small cell lung cancer 887, 928
 - Verapamil synergism 661
- Losoxantrone, breast cancer 403
- Luminal epithelial antigen LEA 135 breast cancer prognosis 1099
- Lung cancer
 - Adenocarcinoma neuropathy 923
 - α 1-Adrenergic receptors 884
 - Altered fractionation radiotherapy 208
 - Cell lines glucocorticoid receptors 889
 - Clinical expectations 18
 - Drug resistance, microculture assay 623
 - Endobronchial laser therapy 1128, 1185
 - Epidemiology 682
 - Epidermoid carcinoma treatments 912
 - Evaluation anti-CEA immunoscintigraphy 876
 - Familial clustering 42
 - Intrapericardial cisplatin 591
 - Metastases, surgery 212
 - Multidrug resistance 64
 - Post-therapeutic complications, analysis 883
 - Psychophysical well-being and survival 1195
 - Superior vena cava syndrome 896
 - Tumour markers 1365, 1366, 1374, 1375, 1378, 1379, 1380, 1403
- Luteinising hormone-releasing hormone analog binding mammary cell membranes 668
- Lymphadenectomy 75, 77
- Lymphoedema, assessment of treatment need 1489
- Lymphomas
 - B-cell line Farage, adhesion molecules on 258
 - Chemotherapy, reduction of side-effects 1484
 - Cytogenetic tests, phorbol dibutyrate 991
 - Dissemination 88
 - EBV association 1090
 - Fludarabine 841
 - Molecular genetics 101
 - Orbital, radiotherapy 984
- MAID regimen with lenograstim 285, 1034
- MDR1 gene expression
 - Detection, polymerase chain reaction 618
 - In AML 605
 - In sarcomas 609
- Medroxyprogesterone plasma levels 603
- Medroxyprogesterone acetate (see also Gestragen) cachexia treatment 1176

Megakaryocyte growth factors in treated thrombocytopenic patients 254

Megestrol acetate

- Breast cancer trial 410
- On body weight 1141
- Plasma levels 603

Melanoma

- Antibody distribution tracing 1000
- Antiemetic prophylaxis 999
- Cell movement inhibition studies 993
- Chemotherapy 996, 997, 999, 1002, 1004, 1005, 1007, 1009, 1012, 1013
- Cutaneous, outpatient surgery 995
- Fotemustine 1010
- HLA class I antigens in patients 994
- Immunotherapy 229, 1002
- Isolation perfusion chemotherapy 635
- Metastases 89
- MR1 and CT clinicopathological correlation 1006
- Neuromyotonia associated 1004
- Oncogene expression, clinical significance 992
- Preoperative cryodestruction of skin 1001
- Prognostic factors 242
- Skin treatment Ir-192 moulds 1008
- Taxotere 998
- Tumour-infiltrating lymphocytes infusion 1003
- Tumour markers 1395

Melanoma cells

- B16, novobiocin on sensitive and resistant 610
- K1735-M2 migration rate inhibition 993

Melanoma vaccine with IL-2 on immune response 228

Melatonin with IL-2, clinical trial 232

Melphalan

- BSO combination trial 647
- Busulfan, bone marrow transplants 840
- Sarcoma 1017

Mesenchymal tumours cytogenetics 133

Mesna

- Breast cancer 411
- Non-Hodgkin lymphoma 977
- Paediatric solid tumours 1106
- Toxicity 592

Mesothelioma

- Combination chemotherapy 279, 1027
- Cryodestruction, chemotherapy 885

Metoclopramide antiemetic treatment 1159

Metastasis

- CD44 variants 84, 88
- Effects of local control 147, 148, 149
- Formation, radioimmunotherapy on 246
- Head and neck cancer 806, 811
- Hodgkin's disease 941
- Integrins 85, 88
- Laminin receptors 86
- Liver 235
- Lymphoma 88
- Melanoma 89, 239

- Non-small cell lung cancer 891, 908, 910
- Occult breast primary 340
- Osteosarcoma to lung 1024
- Renal 244
- Small cell lung cancer 852, 853, 864
- Soft tissue sarcoma to lung 1021
- Metastatic cancer, unknown primary 552, 572
- Methadone, rectal for cancer pain 1135, 1144
- Methotrexate (MTX)
 - Bladder cancer 1297, 1299, 1300, 1301, 1302
 - Breast cancer 362, 374, 384, 390, 400, 409, 414, 422, 458, 488
 - CNS lymphomas 1073
 - Colorectal cancer 471, 525
 - Fibromatoses 1044
 - Fibrous histiocytoma of bone 1023
 - Non-Hodgkin lymphoma 981
 - Osteosarcoma 1035, 1124
 - Pharmacokinetics 598
 - Soft tissue sarcomas 1025
 - Transport, vincaalkaloids on 667
 - Urothelial cancer 1297, 1299, 1300, 1301, 1302
- Mitomycin
 - Analog BMY-25067 phase I study 646, 652
 - Analog KW-2149 phase I trial 641
 - Colorectal evaluation 510
 - Combination therapy 281, 384, 407, 414, 425, 488, 489, 582, 738, 747, 768, 1233, 1338
 - Non-small cell lung cancer 880, 897, 913, 915, 917
- Mitoxantrone
 - AML 821
 - Bladder cancer 1301
 - Breast cancer 362, 384, 406, 409, 414, 422, 429, 433, 449, 488
 - Cytotoxicity modulation 611
 - Head and neck cancer 770
 - Non-Hodgkin lymphoma 977, 981
 - Ovarian cancer 735
 - Pleural metastases palliation 1136
 - TNF phase I study 649
- Molecular epidemiology, DNA alterations as markers 16
- Monoclonal antibody
 - Colorectal cancer 238, 267
 - In diagnosis and treatment 17
- Multidrug resistance
 - Anthracyclines structures 65
 - B16 cells 610
 - DNA topoisomerase inhibitors 62
 - Drug transport 63
 - Evaluation, antigenic detection, functional analysis 619
 - FUDR reversal 614
 - Lung cancer 64
 - Microculture assay 623
 - PET studies 116
 - Protein kinase C in 1268
 - Reversal compounds 66, 620
 - S9788 reversal 612, 615, 622
- Multiple endocrine neoplasia syndromes 38
- Multiple myeloma VAD-PECC treatment regimen 838
- Myelodysplasia

- AraC, rhGM-CSF trial 249
- FLAG therapy 820
- Growth factors on 255
- Paediatric treatments assessed 1126
- Myofibrosis in CML 832
- Navelbine (see Vinorelbine)
- Neoplasia multistage evolution 181
- Nervous system tumors
 - Astrocytoma, oxaliplatin 1067
 - Astrocytoma, postoperative chemoradiotherapy 1079
 - Astrocytoma, postoperative radiotherapy 1057
 - Astrocytoma, pre-irradiation chemotherapy 1071
 - Brain glioblastoma diagnostic imaging 1051
 - Brain, MAB-labelled liposome carriers 1052
 - Cerebral gliomas, radiotherapy 1080
 - GBM review of treatments 1076
 - Germ cell, paediatric assessment 1059
 - Glioblastoma pre-irradiation chemotherapy 1071
 - Glioblastoma radioimmunotherapy 1053
 - Glioblastoma, radiotherapy, IFN 1063
 - Glioma brachytherapy 1060
 - Glioma chemoradiotherapy 1056
 - Glioma chemotherapy, flow cytometry predictions 1064
 - Glioma, fotemustine 1055
 - Glioma radiotherapy 1058
 - Intracranial ependymomas, post-operative radiotherapy 1082
 - Lymphomas chemoradiotherapy 1073
 - Medulloblastoma, prognostic factor 1069
 - Metastases in Wilm's tumour 1065
 - Pituitary adenoma radiotherapy 1061
 - Radiotherapy in children 1078
 - Retinoblastoma cells differentiation 1077
 - Supratentorial gliomas, long-term results 1054
- Neuroblastoma
 - Bone marrow transplantation 153, 154
 - Cell detection in peripheral blood 1105
 - DNA ploidy and N-myc prognosis 1095
 - Genetic alterations 1084
 - Molecular pathology 183
 - Retinoids chemotherapy 204
- Neuroendocrine tumours diagnosis and treatment 12
- Neuroepithelioma, peripheral, prospective study 1015
- Neuromyotonia, melanoma associated 1004
- Neuropathy prevention, Org2766 1152
- Neutropenia
 - Antibodies by central venous catheters 1167
 - CSF treatment 269, 270, 271, 272, 273, 274, 275
- Nicotinamide to overcome radioresistance 1218
- N-Nitrosoguanidines carcinogenesis 462, 464
- Non-Hodgkin lymphoma
 - Best treatment in 1993 20
 - Bone marrow transplant 961

- Chemotherapy 959, 960, 962, 964, 965, 967, 973, 977, 979, 981, 982, 983, 987, 989, 990
- CNS treatment 985
- Ethnic-related pattern Israel 966
- Follicular *bcl-2* gene rearrangement 972
- Follicular, prognosis 970
- Gastric treatment options 974
- Gastroduodenal, AIDS-related 975
- Gastrointestinal therapy 960
- IFN, remission 962, 965, 968
- Immunotherapy 961
- In AIDS patients 213, 218, 219
- Lymphocyte resistance-based therapy 990
- Oxaliplatin 980
- Patterns of relapse 963
- PEG, L-asparaginase 978
- Peripheral blood involvement 958
- Peripheral blood progenitor cell transplant 959
- Peripheral T-cell, Milan data 979
- Prognosis, age relation 971
- Radiotherapy 109, 963, 969, 984
- Retinoblastoma gene 957
- Serum ferritin marker 988
- Staging 946
- Stomach, classification and treatment 969
- Synchronous, and renal carcinoma 986
- TNF α therapy 976
- Younger patients therapy 970
- Non-small cell lung cancer
 - Brachytherapy 886
 - Brain metastases 891, 908, 910
 - Chemoradiotherapy 877, 904, 906, 913, 919, 920, 925, 926
 - Chemotherapy and AS101 256
 - Clinical expectations 18
 - Combination chemotherapy 877, 879, 880, 881, 888, 891, 894, 896, 897, 898, 900, 905, 909, 915, 917, 927, 928
 - Endobronchial radiotherapy 907
 - Endoscopic laser therapy 895
 - Fotemustine 890, 891, 892
 - Gemcitabine 882, 893
 - Intraoperative radiotherapy 918
 - Long-term survival 879
 - Lonidamine and MACC regimen 887
 - Neoadjuvant therapy 904
 - Oxaliplatin study 901
 - Ploidy prognosis 921
 - Postoperative radiotherapy, pulmonary function 924
 - Progesterone receptors prognosis 916
 - Radiosensitisation 922
 - Serum albumin prognosis 911
 - Thymopentin 913
- Novantrone breast cancer combination therapy 390
- Novobiocin on sensitive and MDR cells 610
- Nursing care
 - Age specific factors 1463
 - AIDs patients 1519
 - Ambulatory infusional chemotherapy 1488
 - Amblatory patients 1413, 1414, 1418
 - Belgrade policy 1431
 - Benefit of soy fibre enriched tube feeding 1428
 - Bone marrow transplantation 1416, 1419
 - Brachytherapy 1454
 - Breast cancer infusional chemotherapy 1410
 - Changing attitudes and approaches 1501

Chemotherapy standardisation of procedure 1425
 Clinical research 1438, 1440, 1441, 1443, 1460
 Communication in chemotherapy 1522
 Continuity, cervical cancer patients 1447
 Cultural aspects in Israel 1520
 Day care unit 1518
 Elderly leukaemic patients home care 1467
 Haematopoietic growth factors 1415
 Head and neck cancer radiotherapy 1433
 Home care 1509, 1510
 Hospital–community coordination 1424, 1431
 Hyperthermia 1411
 Immunotherapy 1408
 In day-hospital in Pisa, Italy 1470
 “Informed consent”, information required 1429
 Intensive care unit 1417, 1453
 Intervention on chemotherapy side-effects 1484
 Isracal stoma rehabilitation service 1432
 Kahler patients home treatment 1422
 Liver transplants critical care unit 1421
 Marie Curie community service 1432
 Membership of ethical committee 1451
 New developments 1409
 Norwegian nurse consultants 1461, 1494
 Nursing diagnoses 1450
 Oral assessment instrument 1435
 Outpatient chemotherapy, hospital environment 1439
 Outpatient clinic in Italy 1521
 Outpatient medication 1462
 Pain management in home care 1487
 Palliative surgery 1512
 Patient administration management system 1449
 Patient education 1420
 Patients’ emesis 1430, 1483
 Patients’ stress 1473
 Paediatric 1468
 Personality qualities 1444, 1464
 Preparation for chemotherapy 1456
 Preventative oral, MTX chemotherapy 1486
 Radiation oncology guidelines 1426
 Resuscitation decisions 1427
 Rehabilitation 1422
 Role in breast cancer 1464, 1469
 Role of nurse manager 1448
 Safe handling of antineoplastic drugs 1475
 Stem cell transplantation 1412, 1416
 Stress in cancer nursing 1479
 Symptom control in patients 1482
 Terminal patients 1434, 1504, 1506, 1507, 1509
 Transcultural 1516
 Use of feelings 1513
 Value to patients 1471
 Widowers’ needs 1493

Nursing education

Antineoplastic drugs 1475
 Clinical research 1440, 1442
 Critical care 1442
 Emergency team, fire hazards 1436
 Intensive care unit 1417, 1453
 Marie Curie 1432
 Multimedia and computer training 1434
 Palliative care 1511
 Paediatric care 1468
 Radiation oncology 1426
 Swedish analysis 1480

Oncogene (see also Gene)

- Activation in thyroid tumours 9
- bc12* homology with BHRF1 1090
- C-Ha-Ras rearrangement and radiosensitivity 1228
- C-MOS rearrangement and radiosensitivity 1228
- C-*myc*, breast cancer 1098
- C-*myc*, melanoma 992
- E6/E7 transcription control 3
- Expression control 6
- HER-2/*neu*, breast cancer 323, 1089, 1098
- HER-2/*neu*, gastrointestinal cancer 1098
- N-*myc*, neuroblastoma 180, 1095
- p53, melanoma 992
- Prad-1, head and neck cancer 790
- PTC, thyroid tumours 98
- Suppression by LEA.135 1099

Oesophageal cancer

- Brachytherapy with external radiotherapy 537
- Chemoradiotherapy, surgery 580
- Conservative chemoradiotherapy 1233
- Delayed gastric emptying after surgery 538
- Diagnosis and staging 128
- 5FU, carboplatin, cisplatin 559
- Laser therapy 126
- Palliative surgery 129
- Photodynamic therapy 1182
- Presurgical cisplatin, etoposide 557
- Presurgical radiochemotherapy 545
- Prevention of chemotherapy-induced anaemia 259
- Prognostic factors 125
- Radical resection 124
- Radiotherapy 127
- Second primary 550
- Stent insertion palliation 1147
- VATS surgery 75

Oestrogen receptor, breast cancer

- CEA levels 307
- Determination methods 309

Ondansetron antiemetic in chemotherapy 1116, 1150, 1151, 1159, 1175, 1178, 1491

Org 2766 prevention of CT neuropathies 1152

S-Osteocalcin breast cancer prognosis 310

Osteosarcoma

- limb salvage 1040, 1043
- Margins, local recurrence correlations 1401
- MTX therapy 598
- Paediatric, high dose MTX 1124
- Paediatric, histological subtypes 1123
- RB gene prognostic factor 1371

Ovarian cancer (see also Gynaecological cancer)

- Cells carboplatin, radiation cross-resistance 607
- Chemotherapy IL-3 265
- Chemotherapy, value of CSF 263
- IFN treatment 47
- Laparoscopic surgery 74, 77
- p53 expression, differentiation 1086
- Prognostic value of EGF receptors 262
- 17q association 1083
- Tumour markers 1384, 1399, 1401

Oxaliplatin (L-OHP)

- Absence of renal toxicity 589
- Astrocytoma 1067
- Colorectal cancer trial 511
- Neurotoxicity 632
- Non-Hodgkin lymphoma 980
- Non-small cell lung cancer 901

- p53
 - Colorectal cancer 530
 - Differential diagnosis 1386
 - Expression in cell differentiation 96
 - Gene mutation in cancers 37, 100
 - Gene transcriptional regulator 30
 - On melanoma 992
 - Molecular basis of function 99
 - Ras oncoprotein function 97

- PS2 protein, breast cancer marker 392

- P-glycoprotein
 - Antigenic detection and functional analysis 619
 - ATP-dependent drug extrusion 606
 - Expression and daunorubicin accumulation 621
 - Flowcytometric detection 613
 - In multidrug resistance 63, 64, 65
 - Relevance in leukaemic patients 608

- Paediatric cancer
 - Alternative treatment by parents 1058
 - Ambulatory i.v. treatment 1414
 - Anthracyclines, late cardiac effects 1108
 - Bone marrow transplants 151, 152, 153, 154, 155, 156
 - Bone salvage surgery 1122
 - Brain 110, 1066, 1068
 - Chemotherapy antiemetic granisetron 1117, 1118
 - Chemotherapy antiemetic ondansetron 1116
 - Chemotherapy antiemetic tropisetron 1119
 - Chemotherapy ifosfamide, antiemetics comparison 1117
 - Chemotherapy on growth hormone 1107
 - CNS radiotherapy 1078
 - Ewing's sarcoma long-term analysis 1104, 1121, 1125
 - Germ cell, chemotherapy 1059, 1101
 - Hodgkin's 109, 941, 944, 945
 - Immunity correlation 1070
 - Indwelling central venous access devices 1112
 - Intracranial germ cell MAKEI treatment 1102
 - Lumbar, crista punctures, pain reduction 1490
 - Myelodysplastic syndrome treatments 1126
 - Myeloid leukaemia cytogenetic aberrations 834
 - Neuroblastoma 153, 154, 180, 183, 204, 1084
 - Non-testicular germ cell, MAKEI treatment 1101
 - Nursing 1468
 - Osteosarcoma high dose MTX 1124
 - Osteosarcoma, histological subtypes, prognosis 1123
 - p53 mutation 37
 - Parenteral nutrition influence, chemotherapy tolerance 1110
 - Patients implantable infusional devices 1446
 - Preoperative chemotherapy 33
 - Radiotherapy, quality assurance 112, 1120
 - Radiotherapy video 1465
 - Rhabdomyosarcomas 26, 108, 1036, 1109
 - Sarcomas, immunological changes 1115
 - Soft tissue sarcoma northern Israel 1114
 - Solid, ifosfamide and MESNA 1106
 - Solid, northern Israel analysis 1113

- Splenic abscess during ALL chemotherapy 1111
- Surgical oncology assessments 33
- Wilm's 111, 1065, 1103
- Paget's disease treatment 349
- Pain
 - Antihistamines for taxol-induced 604
 - Bone metastases clodronate infusion 1130
 - Bone metastases, irradiation comparison 1142
 - Calcitonin nasal spray 1132
 - Coeliac plexus 1143
 - Medication compliance in outpatients 1462
 - Methadone suppositories 1144
 - Methadone treatment pharmacokinetics 1135
 - Morphine administration route 1129
 - Reduction in lumbar, crista puncture in children 1490
 - Sleep disorders 1505
- Palliative treatment
 - Bone metastases, orthopaedic surgery 1145
 - Care education 1140
 - Dexamethasone, brain tumour 1131
 - Dysphagia treatment comparisons 1147
 - Liver metastases, percutaneous ethanol injection 1139
 - Lung cancer endobronchial laser therapy 1128
 - Management of intestinal obstruction 1146
 - Megestrol acetate and weight loss 1141
 - Mitoxantrone, pleural metastases 1136
 - Morphine 1127, 1129
 - Pain control 171, 172
 - Polish experience 173
 - Program 174
 - Quality of life assessment 170
 - Surgical 169
- Pamidronate
 - On bone mechanical properties 1154, 1160
 - Renal function tolerance 282
- Pancreatic cancer
 - 5FU, folinic acid, cisplatin 553
 - 5FU, mitomycin, doxorubicin 582
 - Gemcitabine trial 541
 - GNRH analogs 575
 - Somatuline treatment 548, 575
 - Surgery 551
 - Topotecan trial 542
 - Vinorelbine 563
- Papilloma viruses, oncogenes 3
- PEG-L-asparaginase, non-Hodgkin lymphoma treatment 978
- Penile cancer chemotherapy 1317
- Phase 1 studies
 - AS101 158
 - Biological response modifiers 161
 - Bioreductive drugs 159
 - Bryostatin I 157
 - Polymer-drug conjugates 162
 - RO 40-8757 202
- Phorbol-12, 13-dibutyrate lymphoma tests 991
- Phosphonacetyl-L-aspartic acid (PALA) colorectal cancer treatment 493

- Photodynamic therapy
 - Experimental small bowel anastomoses 1184
 - Kaposi's sarcoma 1183
 - Oesophageal cancer 1182
 - Squamous cell lung cancer 1185
 - Superficial skin cancer 1186
 - With 5-amino-levulinic acid 1186
 - With chlorins 1187
 - With dihaematoporphyrin ethers 1184
- PIBIDS inherited NER defects 141
- Pilocarpine in head and neck radiotherapy 773
- Piparubicin prostate cancer treatment 1336
- Piperacillin-tazobactam and amikacin fever treatment 1157
- Piracetam antineoplastic effect 465
- Plasminogen activators, breast cancer prognosis 292, 316, 317
- Platelet-derived growth factor production, IFN stimulation 250
- Pleuromesothelioma, viral DNA evidence 467, 468
- Positron emission tomography (PET)
 - Brain oligodendrogliomas assessment 117
 - C-11-thymidine tumour studies 118
 - F-18-fluorodeoxyglucose tumour studies 119, 492
 - Soft tissue sarcoma grading 1019
 - Tissue pharmacokinetics of drugs 114, 116
 - Treatment response with metabolic markers 115
- Prednimustine non-Hodgkin lymphoma treatment 989
- Prednisolone non-Hodgkin lymphoma treatment 973
- Prednisone
 - Breast cancer therapy 422
 - Hodgkin's disease therapy 931
- Procainamide on cisplatin toxicity 670
- Procarbazine anaplastic astrocytoma treatment 1079
- Progesterone
 - Endometrial cancer prognosis 690
 - Receptors NSCLC prognosis 916
- Prostate cancer
 - Androgen ablation 1319
 - Biological markers 82
 - Chemotherapy 1325, 1326, 1328, 1336, 1338, 1344
 - Family aggregation 1320
 - Hormonal therapy 1329, 1341, 1344
 - Hormone resistance 1325, 1326, 1328, 1332, 1336, 1339
 - Molecular genetics 81
 - Oestrogens and progestogens on PC-3 cells 1331
 - Origin and evolution 78
 - Prostatectomy margins 1321
 - PSA as prognostic factor 1322, 1330, 1334, 1340
 - Radiotherapy 1322, 1327, 1333, 1334, 1337, 1341
 - Radiotherapy, hyperthermia 1335
 - Radiotherapy, orchidectomy 1323
 - Screening 1340

Self-assessment after radiotherapy 1324
 Somatulin treatment 1332, 1339, 1342
 Surgery 83, 1341
 Tenascin expression 1319

Psychosocial oncology

Acceptability of follow-up of asymptomatic patient 1202
 Alternative treatments of children by parents 1508
 Attitude to smoking of hospice staff 1474
 Breast cancer experiences 1469
 Breast cancer patients survey 1196
 Breast cancer treated women, courses for couples 1499
 British "Talking about cancer" service 1496
 Cancer chemotherapy patients coping support 1478
 Cancer prevention Moscow 1481
 Cancer stressors, salutogenesis 1473
 Changing nurses attitudes 1501
 Cigarette advertising 1477
 Clinical trials, quality of life 1458
 Cultural aspects in Israel 1520
 Day care unit, patient satisfaction 1518
 Developing cancer education 1476
 Early coping with cancer 1497
 Elderly breast cancer patients 1466
 French ethical committee 1451
 Hospital staff, personality qualities 1444
 Hypothermia prevention of alopecia 1437
 Informed consent, European randomised trials 1188
 Israel stoma rehabilitation service 1495
 Italian patients knowledge of diagnosis 1189
 Lung cancer well-being and survival 1195
 Mastectomy vs. lumpectomy 1192, 1193
 Norwegian cancer society patient care 1461, 1494
 Pain management in home nursing 1487
 Palliative care 1503
 Palliative surgery 1512
 Patients' feeling in waiting room, post-treatment check up 1200
 Physicians coping strategies 1190
 Preparation for chemotherapy 1456
 Progressive muscle relaxation 60
 Quality of life in hospital-at-home care 1205
 Rehabilitation 1492
 Rehabilitation after bone marrow transplantation 1500, 1502
 Rehabilitation in a specialist centre 1498
 Repressiveness in cancer patients 1198
 Sexual dysfunctions 1194
 Sleep disorders 1505
 Spanish oncologists burn-out syndrome 1203
 Stress and health of nurses 1191
 Swedish patients' hopes and expectations with care 1204
 Symptom control in cancer patients 1482
 Telephone contact after radiotherapy 1197
 Unconscious communication in chemotherapy 1522
 Value of antiemetic prophylaxis 1199
 Video on radiotherapy for children 1465
 Widowers' needs 1493

Quality assurance

Antiemetic therapy 1168
 Brachytherapy 1454
 Breast cancer therapy 194, 195, 335
 Cancer care, key issues 1423
 Chemotherapy 1425, 1459, 1460
 Conformal techniques 121
 European radiotherapy department 1278

- Influence of patients' criticism 1457
- Information to patients 1445
- Paediatric radiotherapy 112, 1120
- Radiation oncology nursing 1426
- Quality of life
 - After bone marrow transplant 1500, 1502
 - Ambulatory patients 1413, 1414, 1418, 1422
 - Assessment implementation 55
 - Assessment in phase I study 1458
 - Assistance, brain tumours 1072
 - Breast cancer patients 1196
 - Breast cancer treatment 58, 448
 - Cachexia 1176
 - Childhood brain tumour 1068
 - Clinical investigation 56
 - Curative or palliative treatments 59
 - Glioma radiotherapy 1058
 - Hospital-at-home 1205
 - Levels of decision making 57
 - Mastectomy vs. lumpectomy 1192, 1193
 - Most important determinants, Turkish analysis 1201
 - Non-small cell lung cancer 892
 - Palliative treatment 169, 170, 172, 173, 1132
 - Patients treated for childhood cancers 1472
 - Prechemotherapy nervousness 1177
 - Progressive muscle relaxation 60
 - Prostate cancer patients 1324
 - Sexual dysfunctions 1194
 - Value of nursing 1471
 - Wilm's tumour 1103
 - With short life expectancy 1057
- Radiation
 - Carboplatin cross resistance 607
 - Damage, intestinal 499
 - Tolerance of normal tissues 35
- Radiobiology
 - Cell survival curves polynomial approximation 1220
 - DNA double strand breaks 1226
 - Dose-dependent neuropeptides expression 1212
 - Etoposide and radiation on mouse tumours and feet 1211
 - Fibroblast differentiation after irradiation 1215
 - Fibroblast sensitivity correlation, radiotherapeutic 1206
 - Fibroblast sensitivity, DNA damage 1208
 - NK cell activity in patients 1222
 - Of tumours 21
 - Protection by heat shock protein 70 1213
 - Radiosensitivity of tumour primary cultures 1217
 - Skin cancer model 1229
 - Tumour oxygenation after carbogen administration 1209
 - Tumour oxygenation and haematocrit level 1210
 - Tumour radioresistance, use of nicotinamide 1218
- Radioimmunoscintigraphy
 - Colorectal cancer 478, 480
 - Glioblastoma 1053
- Radiosensitisers 67, 71, 72, 498, 508, 922, 1230
- Radiotherapy
 - Adenoma 1061
 - Bladder cancer 1280
 - Bladder cancer organ preservation 49
 - Bone marrow damage 1256
 - Boost dose effectiveness 1252

- Brain, helmet technique accuracy 1243
- Brain tumours 110
- Brain vascular malformations 1062
- Branched polypeptide protection 1260
- Breast cancer 167, 194, 332, 337, 351, 357, 359, 360, 361, 363, 364, 381
- Breast conservation 342, 351, 352, 355, 359
- Cerebral gliomas 1080
- Cerebral metastases 1264
- Cervical cancer 28, 695, 697, 700, 703, 706
- Childhood CNS tumours 1078
- CNS prognostic factor 1219
- Colorectal cancer postoperative 476, 479
- Colorectal cancer preoperative 474, 479, 1265
- Colorectal cancer radical 515
- Conformal 120, 121, 150, 1223, 1232
- Craniopharyngioma 1273
- Dose-rate effects 163, 164, 165, 166, 167, 168
- Dosimetry, scattered radiation 1271
- Electron beam, skin-sparing grids 1248
- Emesis treatment 1181, 1250
- Endometrial 705, 716
- Errors in patient set-up 1245
- Fibrosis after 1206
- For surgeon and medical oncologist 32
- Gastric cancer 556, 1257
- Glioblastoma 1063
- Glioma 1056, 1058
- Glutathione marker 1225
- Head and neck cancer 753, 754, 755, 756, 760, 763, 764, 765, 773, 784, 787, 791, 800, 802, 809, 815, 818, 1239
- Heavy charged particles 123
- Hodgkin's disease 109, 930, 933, 937, 938, 939, 947, 952, 954, 955
- Hyper and accelerated fractionation 205, 206, 207, 208, 498, 693, 749
- Hyperthyroidism after 1272
- Hypoxia and hyperfractionation 1227
- Hypoxia modification 67, 71, 72
- Induced fibrosis 1262
- Induced hearing loss 1242
- Induced hyperprolactinaemia 1244
- Induced lung injury 1249
- Induced pneumonitis, tobacco smoke effect 1246
- Internal mammary nodal 348
- Intracranial ependymomas 1082
- Kaposi's sarcoma 216, 220, 221, 1240
- Late reacting tissues α/β values 1247
- Liver intraoperative tolerance 1214
- Long-term morbidity after 10
- Low LET, $\omega 3$ fatty acids 1224
- Lung cancer 883, 886, 906, 907, 918, 919, 920, 922, 924, 925, 926
- Magnetic resonance imaging 1266, 1267
- Melanoma 1008
- Mesothelioma 1046
- Morbidity reporting 54
- Neutron 1239, 1265
- Neutropenia prevention 274
- Non-Hodgkin lymphoma 109, 963, 984, 985
- Non-homogeneous dose distributions 122
- Oesophageal cancer 127, 537, 545
- On hypothalamus–pituitary function 1261
- Paediatric quality assurance 112
- Pelvic 1231, 1232
- Predictive assays 21
- Prevention of heterotopic bone formation 1259
- Prostate cancer 1322, 1327, 1333, 1334, 1335
- Radiation field reconstruction 1274
- Reconstructive surgery 1253
- Rectal cancer, organ preservation 51

Retinoblastoma 113
Rhabdomyosarcomas in children 26
Sensitivity of oral cavity epithelium 1241
Shielding block costs 1263
Soft tissue sarcomas 11, 53, 108, 1049
Spleen in CML 824
Spinal cord compression 1515
Stereotactic 1235
Target volume, dose heterogeneities 1236
Tolerance limit and tumour dose 1251
Tolerance of normal tissue 35
Treatment gap isoeffect dose 1234
Uterine cancer 707, 1258
Vulvar cancer 714
Wilm's tumour 111
With chemotherapy, intestinal damage 499
With fotemustine on lung cancer cells 1216
With hyperthermia 1270, 1275, 1335
With IL-2 on metastasis formation 246
With immunotherapy 230
With nicotinamide 1230
With tamoxifen 353

Razoxane

Colorectal cancer radiotherapy 508
Soft tissue sarcoma radiotherapy 1038

Renal cancer

adjuvant treatment 19, 1313
Chemotherapy 1307
Chromosomal alterations 134
FUDR infusion 630
IFN 1307
IFN, 5FU 1311
IFN, IL-2 47, 243, 1308, 1309, 1316
IFN, radiotherapy after surgery 234
IL-2 and LAK cells 244
Immunotherapy trial 225, 233
Multistage evolution 181
Outpatient treatment 1418
P21 protein in serum 1305
Surgery 83
Taxotere 1310
Toremifene 1306
Tumour markers 1388
Wilm's tumour 175, 176

Retinoblastoma

Cell differentiation 177
Cell line Y-79 differentiation 1077
Radiotherapy 113

Retinoic acid

Metabolism inhibition 672
Receptors as targets 655
Therapy in APL 828

Retinoids

Acute promyelocytic leukaemia therapy 203
As differentiating drugs 7, 200
Cell growth inhibition, tamoxifen 666
Clinical trials 201, 225
IFN combination therapy 226
IFN, radiation on cells 230
Neuroblastoma therapy 226
Solid tumour therapy 202

Rhabdomyosarcomas in children

- Current therapy 26
- DNA ploidy analysis 1037
- Progress in treatment 1109
- Radiotherapy 108

Rhabdomyosarcomas prospective study 1015

Roferon (IFN α 2) disseminated melanoma treatment 239

RP 60475 phase I and pharmacokinetic study 653

S 9788 (triazaminopiperidine) on MDR cells 612, 615, 622

Sarcoma

- Bone tumours, limb salvage 1040, 1041, 1043
- Chemotherapy 1015, 1017, 1018, 1023, 1025, 1034, 1044, 1046, 1050
- Fibromatosis chemotherapy 1044
- Fibromatosis long-term outcome analysis 1014, 1022
- Fibrous histiocytoma treatments 1023, 1033
- Limb, hyperthermia, adriamycin 1039
- MDR-1 and GST π gene expression 609
- Osteo, pulmonary metastases treatment 1024
- Osteogenic HD chemotherapy, surgery 1035
- Paediatric, immunological changes 1115
- Primary bone tumour resection 1036
- Radiotherapy 1014, 1022, 1024, 1031, 1038
- Small round blue cell prospective study 1015
- Soft tissue, bone marrow transplant 154
- Soft tissue, Canadian tumour bank/data base 1028
- Soft tissue, cisplatin 1045
- Soft tissue DNA ploidy prognosis 1016, 1037
- Soft tissue, extremities, surgery 1048
- Soft tissue, hyperthermia, chemotherapy 651
- Soft tissue, limb preservation 53, 1017
- Soft tissue, lung metastases surgery 1021
- Soft tissue, MAID treatment 285
- Soft tissue MTP/PE treatment 1026
- Soft tissue multimodality treatment 11
- Soft tissue, neoadjuvant chemotherapy 1018
- Soft tissue, paediatric, northern Israel 1114
- Soft tissue, paediatric radiotherapy 108
- Soft tissue, PET grading 1019
- Soft tissue, postoperative radiotherapy 1049
- Soft tissue, razoxane 1038
- Soft tissue, r-TNF α , melphalan 227
- Soft tissue, surgery, brachytherapy 1029, 1030
- Soft tissue, surgery, radiotherapy 1022, 1031, 1032
- Soft tissue, survival prognostic factors 1042
- Soft tissue, taxotere 1020
- Soft tissue xenografts, radiocurability 1221

Signal transduction inhibition, anticancer therapy 157

Small cell lung cancer

- Adjuvant therapy 856
- Cells, removal from bone marrow 848
- Chemoradiotherapy 858, 862, 870
- Clinical expectations 18
- CNS metastases 852
- Combination chemotherapy 283, 844, 845, 846, 847, 852, 855, 857, 858, 861, 862, 863, 865, 869, 871, 873, 875
- Etoposide 850
- Long-term survival 867, 870
- Monoclonal antibodies 864
- Neurological cognitive impairment 851

- Pericardial metastases 853
- Standard vs. palliation chemotherapy 868
- Taxotere trial 849
- Theophylline 871
- TNM staging 854
- Tropisetron antiemetic 874
- Tumour markers 866, 872
- Somatostatin
 - analogs, breast cancer treatment 91
 - Analogs, pancreatic cancer treatment 548, 575
 - Analogs, prostate cancer treatment 1332, 1339, 1342
 - Levels after radiotherapy 1258
 - Receptor imaging, lymphoma 946
 - Receptors in cancers 91, 95
- Spinal cord compression, prevention of deambulation 1515
- SR423 chemoembolisation microcapsules 657
- Superior vena cava syndrome treatment and response 896
- Superoxide dismutase on radiofibrosis 1262
- Supportive care
 - Bronchoalveolar lavage in pneumocystis carinii 1162
 - Dysphagia treatment 1147
 - Emesis prevention 1149, 1150, 1151, 1155, 1158, 1159, 1161, 1164, 1166
 - Empirical fever therapy 1157
 - Erythropoietin for anaemia 1173
 - Fracture repair 1160
 - Hypersensitivity to carboplatin 1163
 - Neutropenia, antibiotic dose administration 1167
 - Neutropenia, imipenem therapy 1180
 - Nutritional support gastrostomy 1174
 - Prechemotherapy nervousness 1177
- T-lymphocyte tumour antigen recognition 5
- Tamoxifen (TMX)
 - Advanced breast cancer 396, 404, 456
 - IFN combination on tumour variables 295
 - Long-term treatment 388, 399
 - Melanoma 996, 997, 1005, 1013
 - On homocysteine level 596
 - On MDR cells 620
 - Pharmacokinetics 594
 - Primary treatment, elderly breast cancer 378
 - Radiotherapy, elderly breast cancer 353
 - Serum lipid changes 385
 - Thromboembolic accidents 367
 - Trial in healthy women 371
 - Uterine tumours after breast cancer treatment 375
 - With retinoids on cell growth 666
- Taxol
 - Breast cancer treatment 413, 423, 435, 636
 - Cytotoxicity, gastric carcinoma cells 669
 - Metabolism 583
 - Ovarian cancer 723
 - Pain treatment 604
- Taxotere
 - Breast cancer treatment 437
 - Colorectal cancer 535

- Gastric cancer 539
- Head and neck cancer 758
- Melanoma 998
- Small cell lung cancer 849
- Renal cancer 1310
- Soft tissue sarcoma 1020
- Toxicity, premedication protection 1148, 1169
- Tegafur
 - Breast cancer, with folinic acid 451
 - Leucovorin, phase I study 648
- Teicoplanin antibiotic prophylaxis during immunotherapy 245
- Terminal patients
 - Coeliac plexus neurolysis 1143
 - Home-care difficulties 1506
 - Hospice in-patient and home-care programs 1504
 - Lymphoedema treatment 1489
 - Palliative care 1434, 1503, 1509
 - Resuscitation decision 1427
 - Sleep disorders 1505
- Testicular germ cell tumours
 - Beilinson medical center 1359
 - Chemotherapy 1347, 1348, 1350, 1351, 1352, 1353, 1356, 1357, 1358, 1359
 - Chemotherapy toxicity 1351, 1354, 1357
 - Cytogenetics 130
 - Elderly patients 1358
 - Extragenital germinal tumours report 1360
 - Familial risk 1362
 - Fertility in patients 1355
 - Fetal H19 gene 1345
 - Long survival 1356
 - NSE not prognostic 1361
 - p53 mutant 1087
 - Radiotherapy 1346, 1348, 1359
 - Residual mass 1356, 1363
 - Surgery 1353
 - Surveillance 1348, 1349
- TFX-thymomodulin in radioimmunotherapy 381
- Theprubicin, breast cancer combination therapy 402
- Thiotepa breast cancer therapy 419
- [¹⁴C]Thymidine PET studies of tumours 116, 118
- Thymidylate synthase, colorectal cancer prognosis 485
- Thymomas chemotherapy 983
- Thymopentin
 - And analogs on cell proliferation 240
 - Prophylaxis during chemotherapy 248
- Thymosin- α 1 melanoma treatment 1011
- Thymostimulin
 - Breast cancer 401
 - Colorectal cancer 470
 - Liver disease 236, 237
 - Oesophageal cancer 545
- Thyroid tumours, oncogene activation 9

Tissue-specific (TPS) antigen, breast cancer 319, 326

Topoisomerases

In DNA recombination and repair 145
Ovarian cancer 741

Topotecan (CPT analog)

Colorectal cancer 490
Continuous infusion 639
Non-small cell lung cancer 899
Ovarian cancer 722
Pancreatic cancer 542

Toremifene (antioestrogen) renal cancer treatment 1306

Transforming growth factor β

On lung cancer cell lines 251
Production IFN- β stimulation 250

Transfusion-associated graft vs. host disease, Hodgkin's 953

Treosulfane ovarian cancer treatment 725, 726, 729, 730

Trilostane breast cancer therapy 454

Tropisetron antiemetic

Cisplatin chemotherapy 1150
High-dose chemoradiotherapy 1155
Melanoma 999, 1199
Ondansetron comparison 1178, 1491
Optimal treatment 1179
Paediatric pharmacokinetics 1119
Small cell lung cancer 874

Tumour antigens 2, 5

Tumour growth modulation by heparin-like molecules 31

Tumour hypoxia 70, 71, 72

Tumour markers

Ascites fibronectin 1392
Bladder cancer serum 1397
Breast cancer 136, 137, 138, 139, 315, 392, 438
Breast cancer adhesion receptor 1369
Breast cancer β 2-integrin overexpression 1368
Breast cancer CA15-3, 1377, 1381, 1382
Breast cancer CA-125 1396
Breast cancer cathepsin D 1389
Breast cancer IL-2 receptors 1400
Breast cancer MCA 1367, 1407
Breast cancer p53 1391
Breast cancer serum markers 1390, 1405
Breast cancer TPS 1383
Bronchial dysplasia differentiation 1364
CA19-9, idiopathic pulmonary fibrosis 1402
CA-125 for LAM 1372
CD44 23
Cell proliferation 189, 191
Cervical cancer SCC 1394
Cervical cancer serum 1404
Chronic liver disease, unreliability 1376
Colorectal cancer CEA 1370, 1398
Colorectal cancer prolactin 1406
Differential diagnosis p53 protein 1386
Digestive cancers NSE 1385

- In diagnosis and treatment 17
- Lung cancer 866, 872
- Lung cancer CEA and ferritin 1378, 1379, 1380
- Lung cancer cytokeratin 1365, 1393
- Lung cancer ganglioside 1403
- Lung cancer HCG 1387
- Lung cancer IL-2 receptors 1366
- Lung cancer serum proteins 1375
- Lung cancer tissue polypeptide antigen 1374
- Melanoma associated antigens 1395
- Melanoma LAK cell activity 1002
- Neuroendocrine 12
- Osteosarcoma RB gene 1371
- Ovarian cancer antigens 1384, 1399
- Ovarian cancer EGF receptor 1401
- Oxygenation 188
- Prostate cancer 82
- Renal cancer 1388
- Serum ferritin 988
- Skeletal metastases serum 1405
- Urothelial tumours 80
- Vascular density 187
- Tumour necrosis factor
 - Mechanism of action and antitumour activity 44
 - Mitoxantrone phase I study 649
 - TNF α , non-Hodgkin lymphoma 976
 - TNF α , sarcoma 1017
 - TNF α , with hyperthermia 659
 - TNF α , with interferon- γ and melphalan 45
 - TNF α with melphalan 227
- Tumour staging, preoperative 29
- Tumour suppressor genes 1, 6, 9, 24, 30
- Urological cancers
 - Biological markers 80, 83
 - Quality of life assessment 56
 - Surgery 79, 83
 - Urothelial chemotherapy 1286, 1295
 - Urothelial prognostic index 1285
- Uterine tumours (see also Gynaecological cancer) after tamoxifen breast cancer treatment 375
- Verapamil
 - Lonidamine synergism 661
 - On MDR cells 612, 620, 622
- Vinblastine
 - Bladder cancer 1297, 1299, 1300, 1301
 - Breast cancer 433, 439
 - Fibromatoses 1044
 - Hodgkin's disease 934
 - Melanoma 1007
 - Renal cancer 1313, 1315
 - Split dose vs. bolus 633
 - Testicular cancer 1347
- Vinca alkaloids
 - Multidrug resistance 63, 64
 - Neuropathy prevention 1152
 - Non-small cell lung cancer 877
 - On MTX transport 667
- Vincristine

- Anaplastic astrocytoma 1079
- Breast cancer 414, 458
- Melanoma 1004
- Non-Hodgkin lymphoma 973, 983
- Paediatric sarcoma therapy 1125
- Small cell lung cancer 844, 845, 852, 865, 869
- Soft tissue sarcoma 1205

- Vindesine
 - Breast cancer 425
 - Non-small cell lung cancer 840, 913, 915, 923, 928
 - Renal cancer 1314

- Vinorelbine (Navelbine)
 - Breast cancer 406, 407, 418, 430, 446, 449, 460
 - Colorectal cancer 532
 - Hodgkin's disease 949
 - Non-small cell lung cancer 881, 888, 900, 902, 905
 - Oesophageal cancer 565
 - Pancreatic cancer 563

- Vorozole (R83842)
 - Breast cancer therapy trial 455
 - Pharmacology 394

- Vorozole-racemate (R76713) breast cancer therapy 442

- VP-16 (see also Etoposide)
 - Breast cancer 266
 - Gastric cancer 549
 - Germ cell tumours 276

- Wiedeman–Beckwith syndrome, cytogenetic studies 176

- Wilm's tumour
 - Bone marrow transplantation 154
 - Gene WT1 location and expression 175
 - Randomised equivalence trials 1103
 - Wiedeman–Beckwith syndrome 176

- Xeroderma pigmentosum, inherited NER defects 141, 146

- Zilascorb (²H)
 - Phase I pharmacokinetic trial 640
 - Protein synthesis inhibition and cell cycle progression 656, 664

- Zoladex prostate cancer treatment 1343